다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Journal of breast cancer= 한국유방암학회지, v.21 no.2, 2018년, pp.182 - 189
Jung, Yongsik (Department of Surgery, Ajou University School of Medicine, Suwon, Korea .) , Lee, Soo Jung (Department of Surgery, Yeungnam University Hospital, Daegu, Korea .) , Lee, Juneyoung (Department of Biostatistics, Korea University College of Medicine, Seoul, Korea .) , Noh, Woo Chul (Department of Surgery, Korea Institute of Radiological and Medical Science, Seoul, Korea .) , Nam, Seok Jin (Department of Surgery, Samsung Medical Center, Seoul, Korea .) , Park, Byeong-Woo (Department of Surgery, Yonsei University College of Medicine, Seoul, Korea .) , Bae, Young Tae (Department of Surgery, Pusan National University School of Medicine, Busan, Korea .) , Kang, Sung-Soo (Department of Surgery, Cheil General Hospital & Women's Healthcare Center, Dankook University College of Medicine, Seoul, Korea .) , Park, Heung Kyu (Department of Surgery, Gachon University Gil Hospital, Incheon, Korea .) , Yoon, Jung-Han (Departme) , Kim, Je Ryong , Cho, Se Hun , Kim, Lee Su , Moon, Byung In , Jung, Sung Hoo , Lim, Chol Wan , Kim, Sung Yong , Park, Ho Yong , Song, Jeongyoon , Lee, Kwang Man , Park, Sung Hwan , Jeong, Joon , Park, Hae Lin , Kim, Sung Won , Kwak, Beom Seok , Kang, Sun Hee , Cho, Young Up , Gwak, Geum Hee , Park, Yong Lae , Kim, Sang Wook , Han, Sehwan
AI-Helper
PurposeThere are few reports from Asian countries about the long-term results of aromatase inhibitor adjuvant treatment for breast cancer. This observational study aimed to evaluate the long-term effects of letrozole in postmenopausal Korean women with operable breast cancer.MethodsSelf-reported qua...
1 Park EH Min SY Kim Z Yoon CS Jung KW Nam SJ Basic facts of breast cancer in Korea in 2014: the 10-year overall survival progress J Breast Cancer 2017 20 1 11 28382089
2 Goldhirsch A Winer EP Coates AS Gelber RD Piccart-Gebhart M Thürlimann B Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Ann Oncol 2013 24 2206 2223 23917950
3 Howell A Cuzick J Baum M Buzdar A Dowsett M Forbes JF Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 2005 365 60 62 15639680
4 Coombes RC Hall E Gibson LJ Paridaens R Jassem J Delozier T A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 2004 350 1081 1092 15014181
5 BIG 1-98 Collaborative Group Mouridsen H Giobbie-Hurder A Goldhirsch A Thürlimann B Paridaens R Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 2009 361 766 776 19692688
6 Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group Forbes JF Cuzick J Buzdar A Howell A Tobias JS Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 2008 9 45 53 18083636
7 Geisler J Haynes B Anker G Dowsett M Lønning PE Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study J Clin Oncol 2002 20 751 757 11821457
8 Ohsumi S Shimozuma K Ohashi Y Shinji M Hozumi Y Mukai H Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03 Breast Cancer Res Treat 2011 127 143 152 21347648
9 Hozumi Y Suemasu K Takei H Aihara T Takehara M Saito T The effect of exemestane, anastrozole, and tamoxifen on lipid profiles in Japanese postmenopausal early breast cancer patients: final results of National Surgical Adjuvant Study BC 04, the TEAM Japan sub-study Ann Oncol 2011 22 1777 1782 21285133
10 Brady MJ Cella DF Mo F Bonomi AE Tulsky DS Lloyd SR Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument J Clin Oncol 1997 15 974 986 9060536
11 Cella D Hahn EA Dineen K Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening Qual Life Res 2002 11 207 221 12074259
12 Fallowfield LJ Leaity SK Howell A Benson S Cella D Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B Breast Cancer Res Treat 1999 55 189 199 10481946
13 Fallowfield L Cella D Cuzick J Francis S Locker G Howell A Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial J Clin Oncol 2004 22 4261 4271 15514369
14 Whelan TJ Goss PE Ingle JN Pater JL Tu D Pritchard K Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women J Clin Oncol 2005 23 6931 6940 16157934
15 Mincey BA Duh MS Thomas SK Moyneur E Marynchencko M Boyce SP Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors Clin Breast Cancer 2006 7 127 132 16800971
16 Muss HB Tu D Ingle JN Martino S Robert NJ Pater JL Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17 J Clin Oncol 2008 26 1956 1964 18332474
17 Muss HB Adjuvant treatment of elderly breast cancer patients Breast 2007 16 Suppl 2 S159 S165 17728133
18 Partridge AH Wang PS Winer EP Avorn J Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer J Clin Oncol 2003 21 602 606 12586795
19 Cuzick J Sestak I Cella D Fallowfield L ATAC Trialists Group Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial Lancet Oncol 2008 9 1143 1148 18976959
20 Zaman K Thürlimann B Huober J Schönenberger A Pagani O Lüthi J Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07) Ann Oncol 2012 23 1474 1481 22003243
21 Perez EA Josse RG Pritchard KI Ingle JN Martino S Findlay BP Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 J Clin Oncol 2006 24 3629 3635 16822845
22 Brufsky A Harker WG Beck JT Carroll R Tan-Chiu E Seidler C Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer J Clin Oncol 2007 25 829 836 17159193
23 Sestak I Singh S Cuzick J Blake GM Patel R Gossiel F Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial Lancet Oncol 2014 15 1460 1468 25456365
24 Wasan KM Goss PE Pritchard PH Shepherd L Palmer MJ Liu S The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L) Ann Oncol 2005 16 707 715 15817595
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.